PrimaryBid
Third Floor, 20 Old Bailey, London, England, EC4M 7AN, United Kingdom
Overview
PrimaryBid is a technology platform that allows everyday investors fair access to public companies raising capital. PrimaryBid always ensures that retail investors transact at the same time and at the same price as institutional investors. Through PrimaryBid's long-term agreement with the London Stock Exchange, the company has created the infrastructure to seamlessly connect everyday investors with public companies when it matters most.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 8
Sector focus
- Finance
- Financial Services
- FinTech
Investment portfolio
- MaaT Pharma
Led · Equity · Nov 2025
MaaT Pharma focuses on the discovery and development of Microbiome Ecosystem Therapies™ that leverage consortia of gut bacteria to address serious diseases. Its lead asset, Xervyteg®, is being readied for commercialization in Europe with a launch target in the second half of 2026, while preparations are underway for U.S. pivotal studies slated to begin in early 2026 following FDA discussions. The company is also advancing the MaaT033 clinical trial in Europe. To support these programs, MaaT Pharma reported cash and cash equivalents of €22.4 million as of 30 September 2025, a figure that includes a €10.5 million upfront payment from a commercial partner. Management believes current resources will fund operations through February 2026, with the potential to draw a second tranche of European Investment Bank financing that could extend the runway to August 2026. The firm continues to evaluate additional financing options to further bolster its cash position.